Sugi Predict

Sugi Predict / Compounds / SCHEMBL376819

SCHEMBL376819

SCHEMBL376819

CC(C)(C)OC(=O)N1CCCC(CBr)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ GLS O94925 2/20 0.52
▸ HPGD P15428 1/20 0.49
▸ BACE1 P56817 2/20 0.47
▸ ACKR3 P25106 1/20 0.47
▸ CTSD P07339 1/20 0.47
▸ NR1H2 P55055 1/20 0.47
▸ KDM1A O60341 1/20 0.45
▸ FEN1 P39748 1/20 0.45
▸ SCN9A Q15858 1/20 0.45
▸ EPHX1 P07099 1/20 0.43
▸ FPR3 P25089 1/20 0.43
▸ FPR2 P25090 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ PREP P48147 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1974493 1.00 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL1978233 1.00 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL30294023 0.91 NR1H2 (0.49) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL13604586 0.91 NR1H2 (0.49) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL1114093 0.91 NR1H2 (0.49) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL14920966 0.91 NR1H2 (0.49) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL7691100 0.88 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL758457 0.88 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL7685622 0.88 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL25625800 0.87 NR1H2 (0.51) MEN1ALDH1A1MAPTKMT2AGLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4294800-B1 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS INC (US) 2026-05-06 — — EP disclosed
US-20250206745-A1 PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES NODTHERA LTD (GB) 2025-06-26 — — US disclosed
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEIGENE, LTD. (KY) 2025-04-22 — — US disclosed
US-20250084077-A1 ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS ASTEX THERAPEUTICS LIMITED (GB) 2025-03-13 — — US disclosed
WO-2024249252-A1 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 — — WO disclosed
CN-118955490-A O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors 渤健马萨诸塞州股份有限公司 2024-11-15 — — CN disclosed
US-20240316038-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-09-26 — — US disclosed
US-12091409-B2 Ether linked triazoles as NRF2 activators ASTEX THERAPEUTICS LIMITED (GB) 2024-09-17 — — US disclosed
CN-112218863-B O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors 比奥根MA公司 2024-07-12 — — CN disclosed
EP-3782996-B1 NRF2 REGULATORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-04-10 — — EP disclosed
US-20080227777-A1 Pyrazolopyridine derivatives as inhibitors of beta-Adrenergic Receptor Kinase 1 SANOFI-AVENTIS (FR) 2008-09-18 — — US disclosed
EP-1899333-A1 PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF BETA-ADRENERGIC RECEPTOR KINASE 1 Sanofi-Aventis (FR) 2008-03-19 — — EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 — — WO disclosed
WO-2007000241-A1 PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF BETA-ADRENERGIC RECEPTOR KINASE 1 SANOFI-AVENTIS (DE) 2007-01-04 — — WO disclosed
US-5773465-A Tartronic acids, their acetalic ethers and o-esters DOMPE FARMACEUTICI S.P.A. (IT) 1998-06-30 — — US disclosed
US-5656656-A Tartronic acids, their acetalic ethers and O-esters DOMPE FARMACEUTICI S.P.A. (IT) 1997-08-12 — — US disclosed
EP-0667850-B1 TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS DOMPE FARMACEUTICI SPA (IT) 1997-05-28 — — EP disclosed
EP-0667850-A1 TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS. DOMPE FARMACEUTICI SPA (IT) 1995-08-23 — — EP disclosed
CN-1091741-A Tartronic acid and acetal ether thereof and O-ester DOMPE FARMACEUTICI SPA (IT) 1994-09-07 — — CN disclosed
WO-1994010127-A1 TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS DOMPE' FARMACEUTICI S.P.A. (IT) 1994-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084077-A1 ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS NFE2L2, KEAP1, NQO1 MEN1 4549/4885ALDH1A1 598/4885MAPT 1846/4885
US-20250206745-A1 PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES IL1B, NLRP3, NLRP1 MEN1 3038/4885ALDH1A1 226/4885MAPT 3788/4885
US-12091409-B2 Ether linked triazoles as NRF2 activators NFE2L2, KEAP1, NQO1 MEN1 4549/4885ALDH1A1 598/4885MAPT 1846/4885
US-20080227777-A1 Pyrazolopyridine derivatives as inhibitors of beta-Adrenergic Receptor Kinase 1 ADRB1, ADRB3, ADRB2 MEN1 4667/4885ALDH1A1 201/4885MAPT 2365/4885
US-20240316038-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, SAAL1, APOB MEN1 1930/4885ALDH1A1 1839/4885MAPT 438/4885
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist TLR7, TLR1, TLR3 MEN1 3601/4885ALDH1A1 1611/4885MAPT 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.